Shigeo Hashimoto Takashi Kuroha Toshio Yano Naoko Sato Tatsuo Furukawa
10.2169/internalmedicine.55.6470
Intern Med
2016;55(20):3025-3028.
CC BY-NC-ND
https://pubmed.ncbi.nlm.nih.gov/27746443/
Antineoplastic Agents / therapeutic use Bortezomib / therapeutic use Dexamethasone / therapeutic use Immunosuppressive Agents / therapeutic use Multiple Myeloma / drug therapy Thalidomide / therapeutic use
Antineoplastic Agents / therapeutic use Bortezomib / therapeutic use Dexamethasone / therapeutic use Immunosuppressive Agents / therapeutic use Multiple Myeloma / drug therapy Thalidomide / therapeutic use Case Reports Aged Cyclophosphamide / therapeutic use Female Humans Male Middle Aged Treatment Outcome Antineoplastic Agents Immunosuppressive Agents Thalidomide Bortezomib Dexamethasone Cyclophosphamide
PMC5109573
27746443
The Addition of Low-dose Thalidomide to Bortezomib and Dexamethasone for Refractory Multiple Myeloma
2016